Apollomics(APLMW)

FOSTER CITY, CABiotechnology2 H-1B visas (FY2023)

Focus: Apollomics is a public-stage oncology-focused biotechnology company headquartered in Foster City, CA, developing cancer medicines across multiple therapeutic modalities. The company operates with a lean pipeline of early-to-mid stage programs targeting high-unmet-need indications.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Apollomics

AI assessmentNot Hiring

No open roles listed right now. Follow Apollomics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

APL-102

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05055518APL-102 Capsule in Patients With Advanced Solid Tumors

Phase 1

Help build intelligence for Apollomics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pure-play oncology focus with 8 active clinical trials spanning Phase 1 through Phase 3, offering exposure to diverse cancer biology
Public company status provides liquidity, established governance, and career transparency vs. pre-revenue biotech
Pipeline includes Phase 3 asset (uproleselan in relapsed/refractory AML) with near-term value inflection potential

Watch Out For

Zero active job openings at time of analysis signals potential hiring freeze or organizational contraction
Limited public financial data restricts visibility into cash runway, R&D spend, and long-term viability
Early-stage pipeline concentration (6 Phase 1 programs) carries significant clinical and commercial risk with no marketed products to generate revenue

Generated by Claude from Apollomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

APL-501

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT03053466APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Phase 1

APL-101

Metastatic Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (4)

NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Phase 2

NCT04743505Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase 1/2

NCT03655613APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Phase 1/2

+1 more

uproleselan

Relapsed/Refractory AML

Phase 3

Clinical Trials (2)

NCT05054543Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Phase 3

NCT04839341Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

H-1B (2023): 2 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub